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Mutations in the microtubule-associated protein tau,
including P301L, are genetically coupled to hereditary
frontotemporal dementia with parkinsonism linked to
chromosome 17. To determine whether P301L is associ-
ated with fibril formation in mice, we expressed the
longest human tau isoform, human tau40, with this mu-
tation in transgenic mice by using the neuron-specific
mouse Thy1.2 promoter. We obtained mice with high
expression of human P301L tau in cortical and hip-
pocampal neurons. Accumulated tau was hyperphos-
phorylated and translocated from axonal to somatoden-
dritic compartments and was accompanied by
astrocytosis and neuronal apoptosis indicated by termi-
nal deoxynucleotidyl transferase-mediated biotinylated
dUTP nick end-labeling staining. Moreover, P301L tau
formed abnormal filaments. Electron microscopy of sar-
cosyl-insoluble protein extracts established that the fil-
aments had a straight or twisted structure of variable
length and were ;15 nm wide. Immunoelcecton micros-
copy showed that the tau filaments were phosphoryl-
ated at the TG3, AT100, AT8, and AD199 epitopes in vivo.
In cortex, brain stem, and spinal cord, neurofibrillary
tangles were also identified by thioflavin-S fluorescent
microscopy and Gallyas silver stains. Together, our re-
sults show that expression of the P301L mutation in
mice causes neuronal lesions that are similar to those
seen in human tauopathies.
Hereditary frontotemporal dementia with parkinsonism
linked to chromosome 17 is a group of neurodegenerative dis-
eases characterized by early behavioral changes accompanied
by subsequent cognitive and motor disturbances. More than a
dozen families were identified, with diverse but overlapping
clinical features. Pathological changes include selective fronto-
temporal atrophy, neuronal loss, gliosis, and spongiosis in sev-
eral brain areas in addition to abundant filamentous inclusions
composed of hyperphosphorylated tau protein in neurons and,
to some extent, in glial cells (1).
Tau is an axonal, microtubule-associated phosphoprotein in
normal adult brain (2). Tau has tubulin-polymerizing activities
in vitro (3); it establishes short cross-bridges between axonal
microtubules and thereby supports functions in intracellular
trafficking including axonal transport (4). In neurons affected
by tauopathy, tau is hyperphosphorylated and is located not
only in axons but also in cell bodies and dendrites (5, 6). Results
from in vitro studies suggest that disease-causing mutations in
the tau gene result either in the reduced ability of tau to
interact with microtubules or in increased ratios of four-repeat
(4R)1 to three-repeat tau caused by quantitative changes in the
splicing in of exon 10. (7, 8).
To demonstrate that human tau can form filaments in mouse
brains and to reproduce aspects of the human pathology, in-
cluding neurofibrillary tangle formation, in transgenic mice,
we expressed the longest isoform of human tau with the fron-
totemporal dementia with parkinsonism linked to chromosome
17 causing mutation P301L in neurons by using a neuron-
specific promoter. Tau accumulated mainly in neurons of the
neocortex and hippocampus; it was hyperphosphorylated at
distinct sites and formed filaments similar to those present in
human tauopathies.
EXPERIMENTAL PROCEDURES
Constructs and Transgenic Mice—By a PCR-mediated approach, the
human pathogenic mutation P301L was introduced into the cDNA
encoding the longest human brain tau isoform. This isoform contains
exons 2 and 3 as well as four microtubule-binding repeats (21314R,
human tau40). To be able to discriminate P301L tau transgenic from
wild-type tau transgenic mice, a silent mutation was introduced into
the P301L construct that destroys a diagnostic SmaI restriction site.
The cDNA was conferred with a Kozak consensus sequence and was
subcloned into a murine Thy.1.2 genomic expression vector (Dr. Her-
man van der Putten, Novartis, Basel, Switzerland). Vector sequences of
this construct (named pR5) were removed before microinjection. Trans-
genic mice were produced by pronuclear injection of B6D2F1 3 B6D2F1
embryos. Founders were identified by PCR analysis of lysates from tail
biopsies using two different primer pairs. Founder animals were inter-
crossed with C57BL/6 mice to establish lines.
Transgenic mice were screened with oligonucleotides tau-I (O-100,
59-GGAGTTCGAAGTGATGGAAG-39) and tau-K (O-101, 59-GGTTTTT-
GCTGGAATCCTGG-39) and yielded an amplification product of 500
base pairs. A restriction digest of the amplification product by SmaI
confirmed the presence of the P301L transgene. Ten independent trans-
genic lines were generated, four of which had comparable expression
levels as determined by immunoblot analysis.
Antibodies—Antibody HT7 (Innogenetics Inc.; amino acids 159–163,
diluted 1:400) was used to detect human tau specifically; tau-1 (Roche
Molecular Biochemicals) was used to detect both human and murine
tau on immunoblots; AT8 (Innogenetics Inc.; diluted 1:20) was used to
detect tau phosphorylated at epitopes serine 202 and threonine 205;
AT100 (Innogenetics Inc.; diluted 1:100) was used to detect tau phos-
phorylated at serine 212 and threonine 214; AT180 (Innogenetics Inc.;
diluted 1:50) was used to detect tau phosphorylated at threonine 231
and serine 235; 12E8 (Dr. Peter Seubert, Elan Pharmaceuticals; diluted
1:100) was used to detect tau phosphorylated at serines 262 and 356;
conformation-dependent antibody TG3 (Dr. Peter Davies; diluted 1:20)
was used to detect tau phosphorylated at threonine 231 and serine 235;
PHF1 (Dr. Peter Davies; diluted 1:50) was used to detect tau phospho-
rylated at serine 396 and serine 404; AD2 (Dr. Chantal Mourton-Gilles;
diluted 1:500) was used to detect tau phosphorylated at serine 396 and
serine 404; AD199 (Dr. A. Delacourte; diluted 1:1000; Ref. 9) was used* The costs of publication of this article were defrayed in part by the
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to detect tau phosphorylated at serine 199; MC1 (Dr. Peter Davies;
diluted 1:10) was used to detect the conformational ALZ50 epitope; and
rabbit anti-glial fibrillary acidic protein IgG (Sigma, catalog no. G-9269;
diluted 1:400) was used to detect activated astrocytes. For peroxidase
and diaminobenzidine stainings, secondary antibodies were obtained
from Vector Laboratories (Vectastain ABC kits PK-6101 and PK-6102).
For immunofluorescence, secondary antibodies were obtained from Mo-
lecular Probes (ALEXA-FLUOR series).
Immunoblot Analysis—Brains from transgenic and control mice
(aged 3 weeks to 8 months) were weighed and Dounce homogenized in
2.5% (v/v) perchloric acid in phosphate-buffered saline (PBS), allowed to
stand on ice for 30 min, and centrifuged for 10 min at 10,000 3 g. The
supernatants were dialyzed against 50 mM Tris-HCl (pH 7.4), 1 mM
dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride and used for
immunoblot analysis as described, using equal amounts except for
ALZ17, for which only half the amount of extract has been used (10).
Ponceau staining of the membranes was included to confirm loading of
comparable amounts of protein.
Sarcosyl extractions were done as described (10). In brief, brain
tissue of 8-month-old pR5 transgenic and control mice were homoge-
nized in 10 volumes of buffer consisting of 10 mM Tris-HCl (pH 7.4), 0.8
M NaCl, 1 mM EGTA, and 10% sucrose. An Alzheimer’s disease (AD)
brain sample was included as control. The homogenate was spun for 20
min at 20,000 3 g. The supernatant was brought to 1% N-lauroylsar-
cosinate (Fluka, no. 61744), and incubated 1 h at room temperature
while shaking. After a 1-h spin at 100,000 3 g, the sarcosyl-insoluble
pellets were resuspended in 50 mM Tris-HCl (pH 7.4) and stored at 4 °C.
This material was used for both immunoblot analysis and electron
microscopy.
Samples were run on 10% SDS-polyacrylamide gels and electro-
phoretically transferred to a nylon membrane (Hybond-ECL, Amer-
sham Pharmacia Biotech). Residual protein-binding sites were blocked
by incubation with 5% semifat dried milk in Tris-buffered saline (TBS)
and 0.1% Tween 20 for 1 h at room temperature, followed by a 3-h
incubation at room temperature with the primary antibody in TBS and
0.1% Tween 20, 1% semifat dried milk, and 0.02% sodium azide. Anti-
bodies Tau-1 and HT7 were diluted 1:5000 and 1:250, respectively.
After four washes for a total of 30 min in TBS, the membrane was
incubated with a horseradish peroxidase-linked sheep anti-rabbit Ig
(Amersham, NA931) at 1:5000 dilutions for 1 h at room temperature,
followed by a 30-min wash in TBS. The membrane was then incubated
for 1 min in ECL reagent (Vector Laboratories), excess liquid was
removed, and the membrane was exposed to x-ray films. For reuse,
membranes were stripped for 30 min at 50 °C in 100 mM 2-mercapto-
ethanol and 2% SDS in 62.5 mM Tris (pH 6.8).
Immunohistochemistry and TUNEL Staining—Brains from 3–4-
month-old pR5 transgenic mice and an equal number of control mice
(nontransgenic and wild-type human tau transgenic ALZ17 mice; Ref.
11) were used for immunohistochemical analysis. Animals were per-
fused transcardially with 4% paraformaldehyde in saline and sodium
phosphate buffer (pH 7.4). Immunohistological, hematoxylin-eosin, and
combined Holmes and Luxol stainings were done on 4-mm paraffin
sections from brain and spinal cord by using standard published pro-
cedures (12). Some of the sections were pretreated with 5 mg/ml pro-
teinase K in TBS or PBS at 37 °C for 2.5 min for signal enhancement.
Sections were dehydrated in an ascending series of ethanol and flat
embedded between glass slides and coverslips in Eukitt (Kindler). Sec-
tions were stained with thioflavin-S and silver impregnated by Gallyas
(13) and modified Bielschowsky (14) protocols (15).
TUNEL Staining—To detect cells undergoing apoptosis, the peroxi-
dase in situ cell death detection kit (Roche Molecular Biochemicals, no.
1684817) was used. In brief, paraffin-embedded sections were rehy-
drated, treated with 5 mg/ml proteinase K in PBS for 10 min at 37 °C,
washed with ice-cold PBS four times, incubated in 3% H2O2 in methanol
for 5 min at room temperature, and washed again. For a positive
control, sections were incubated in 100 mg/ml DNase I (Roche Molecular
Biochemicals, no. 104132) in 20 mM Tris-HCl (pH 8.0) and 10 mM MgCl2
for 10 min at room temperature. Then, the labeling solution containing
the enzyme terminal deoxynucleotidyl transferase (POD kit) was di-
luted 1:10 and added to the sections for 30 min at 37 °C. For a negative
control, the enzyme was omitted from the labeling solution. Sample
sections were washed, blocked with 2% bovine serum albumin, and
incubated with convert solution (POD kit), washed again, and incu-
bated in 1:10 diluted diaminobenzidine solution (Pierce, no. 1856090)
for 10 min at room temperature to visualize the DNA breaks. Sections
were dehydrated and mounted in Eukitt. To correlate numbers of HT7-
positive neurons with glial fibrillary acidic protein-positive astrocytes
and TUNEL reactivity, positive cells in an area of 0.7 3 0.6 mm of the
somatosensory cortex S1 and the motor cortex M1 were counted in 10
sections per animal.
Electron Microscopy and Immunogold Electron Microscopy—Resus-
pended sarcosyl-insoluble material obtained from brains of transgenic
mice, control mice, and an AD patient were placed directly on carbon-
coated, 300-mesh grids, stained with 2% phosphotungstic acid, and
analyzed by electron microscopy (see below). Samples were also pro-
cessed for immunogold electron microscopy and incubated with the
primary antibody in PBS and 0.1% gelatin for 90 min at room temper-
ature. Antibody AT100 was used at 1:100 dilutions, antibody AT180 at
1:5 dilutions, rabbit antiserum AD199 at 1:50 dilutions, and hybridoma
supernatant TG3 undiluted. As negative controls, filament prepara-
tions from AD brain and transgenic mice were incubated with
a-synuclein-specific antiserum PER4 as well as an antibody against a
PR8 influenza virus surface antigen. In addition, controls were in-
cluded, in which the primary antibody had been omitted. Incubations
were placed on Formvar- and carbon-coated, 300-mesh grids and al-
lowed to evaporate partially. Grids were washed twice in PBS and 0.1%
gelatin and incubated with the respective secondary antibody conju-
gated to 6 nm Au (Sigma) for 30 min in a humid chamber at room
temperature. After two washes in PBS and 0.1% gelatin and one in
water, the grids were blotted, stained with 2% phosphotungstic acid,
and allowed to air dry. Micrographs were recorded at an operating
voltage of 80–100 kV and at nominal magnifications of 3 88,000 and 3
175,000 on a Philips CM12 electron microscope.
RESULTS
Overexpression of Human tau—The neuron-specific elements
of the mouse Thy1.2 promoter were used to express the longest
human four-repeat tau isoform containing the two amino-ter-
minal exons 2 and 3 (21314R), along with human pathogenic
mutation P301L (pR5 construct). Ten founders were obtained,
four of which were used for further analysis on the basis of
their expression levels: By immunoblot analysis of similar
amounts of perchloric acid-soluble protein extracts, as judged
by Ponceau stainings, a strong immunoreactive 66-kDa protein
that corresponded to the transgenic tau band was identified in
animals of some pR5 lines; it reacted with the anti-tau antibody
Tau-1 that recognizes both human and murine tau (Fig. 1A), as
well as with antibody HT7 against human, but not murine, tau
(Fig. 1B). Soluble tau brain tissue levels for line pR5-183 were
;70% of endogenous tau (Fig. 1A, lane 4, upper transgenic
band representing human tau compared with lower bands rep-
resenting the endogenous murine tau isoforms). As expected,
transgenic tau was absent from the wild-type brain protein
extracts (Fig. 1B, lane 8). Amounts of sarcosyl-insoluble tau
(Fig. 1C) were generally higher in the pR5-183 (Fig. 1C, lane 1)
than in our transgenic mice that expresses human tau without
the mutation (ALZ17 line; Ref. 11; Fig. 1C, lane 3). Protein
extracts from pR5-183 mice were therefore subsequently used
for electron microscopy. The transgenic mutant tau in pR5-183
mice was hyperphosphorylated, as indicated by several phos-
phorylation-dependent anti-tau antibodies (data not shown).
To determine the distribution and localization of tau in
brain, a 3-month-old mouse of the pR5-183 line was analyzed
by immunohistochemistry using antibody HT7. Expression lev-
els of human tau were high in hippocampus, fornix fimbriae,
amygdala, spinal cord, and cortex (Fig. 2A), weaker in brain
stem and striatum, and not detectable in olfactory bulb and
cerebellum. A sagittal section of the hippocampus showed nu-
merous HT7-positive pyramidal neurons in the CA1 region but
not in CA3. The mossy fiber projections of the hippocampus
were strongly stained, whereas staining intensity was some-
what weaker in dentate gyrus granule cells (Fig. 2, A and C). In
CA1 pyramidal neurons human tau was present in axons but
accumulated also in cell bodies and apical dendrites (Fig. 2B).
In brain stem, HT7-positive cells were identified, in addition to
axonal spheroids, and cells that expressed tau were strongly
stained, with granular accumulation of tau (Fig. 2D). In addi-
tion, a subset of pyramidal cells in the cerebral cortex was HT7
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immunoreactive. As for CA1 pyramidal cells, we found granu-
lar immunostaining of cell bodies and dendrites (Fig. 2E). In
comparison with wild-type human tau transgenic ALZ17 mice,
staining of cell bodies and dendrites of the dentate gyrus gran-
ule cells was less pronounced in pR5-183 mice, as determined
with antiserum AD199 (Fig. 2, F and G) or antibody HT7 (data
not shown). In other brain areas, staining patterns were com-
parable. Neurofibrillary tangles were identified in spinal cord,
brain stem, and cortical layers 5 and 6 by thioflavin-S fluores-
cent microscopy (Fig. 2H) and Gallyas silver stains (Fig. 2I).
Abnormal Phosphorylation and Conformation of tau—To de-
termine the phosphorylation status of tau in 3-month-old pR5
mice, we used a panel of phosphorylation- and conformation-
dependent anti-tau antibodies. Antibody TG3, a phosphoryla-
tion- and conformation-dependent antibody, stained pyramidal
neurons of the CA1 region of the hippocampus of transgenic
mice (Fig. 3A) but not controls (Fig. 3B). TG3 stained numerous
pyramidal neurons in cortices of transgenic (Fig. 3C) but not
control (Fig. 3D) mice. The conformation-dependent antibody
MC1 that detects the ALZ50 epitope of AD tau stained pyram-
idal neurons of the CA1 region and the cortex of transgenic
(Fig. 3, E and G) but not control (Fig. 3, F and H) mice. The
same staining pattern was obtained with antibody AT180,
which detects tau phosphorylated at threonine 231 and serine
235 (Fig. 3, I–M). Antibody AD199 directed against phospho-
rylated serine 199 stained hippocampal and cortical neurons
moderately, antibody AT8 directed against serines 202 and 205
stained only weakly and was mainly restricted to cortical neu-
rons, whereas antibodies AD2 and PHF1 directed against
serines 396 and 404 did not detect any neurons. Staining with
antibodies 12E8 and AT100 revealed similar patterns in trans-
genic and control mice (data not shown).
Astrocytosis and Apoptosis—To detect activated astrocytes,
we used an antibody against glial fibrillary acidic protein. This
FIG. 1. Immunoblot analysis of tau protein in brains from mice
of pR5 lines. A, tau protein extracted with perchloric acid from brains
of different 3-month-old mice of pR5 lines (lanes 1–7; lane 4, line
pR5-183) and a wild-type control mouse (lane 8) was analyzed by
immunoblotting using anti-tau antibody Tau-1. This antibody recog-
nizes murine and human tau. B, the blot was stripped and reprobed
with HT7, a human tau-specific antibody. The arrow points to the
human tau band. C, sarcosyl-insoluble tau from the brains of 8-month-
old mice of line pR5-183 (lane 1), a wild-type control mouse (lane 2), and
a wild-type human tau transgenic ALZ17 mouse (lane 3) analyzed by
immunoblotting using antibody HT7. The arrow points to the human
tau band.
FIG. 2. Tau immunoreactivity in brain from a 3-month-old
mouse of the pR5 line reveals high expression of human tau. A,
sagittal section of the hippocampus shows HT7-positive pyramidal neu-
rons in CA1. Staining is less intense for dentate gyrus (dg) granule
cells. Also note strong immunostaining of the mossy fiber (mf) projec-
tion in sector CA3 of the hippocampus. B, CA1 pyramidal neurons
accumulate human tau in cell bodies and apical dendrites. C, the mossy
fiber network is intensely stained, revealing transport of human tau
into the axon. D, In brain stem, HT7-positive cells are found with
granular accumulation of tau, in addition to axonal spheroids. E, in
cerebral cortex, a subset of pyramidal cells is HT7-immunoreactive.
Note the intense, granular immunostaining of cell bodies and dendrites.
No immunoreactivity was observed in control mice. F and G, staining of
cell bodies and dendrites of dentate gyrus granule cells with antiserum
AD199 is less pronounced in pR5-183 mice (F) compared with wild-type
human tau transgenic ALZ17 mice (G). H and I, neurofibrillary tangles
are identified in several brain areas including spinal cord by thiofla-
vin-S fluorescent microscopy (H) and Gallyas silver stains (I). Scale
bars: A, F, and G, 100 mm; B–E, 20 mm.
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antibody revealed activated astrocytes in the amygdala and in
cortical areas of transgenic mice that contained numerous tau-
positive neurons (Fig. 4A). No such activated astrocytes were
observed in control amygdala and cortex (Fig. 4B). Also, no
astrocyte activation was found in the hippocampus of trans-
genic mice (data not shown). To identify cells that underwent
apoptosis, we used TUNEL stains and found many TUNEL-
positive neurons in the somatosensory cortex that contained
numerous tau-positive neurons (Fig. 5A). By contrast, only very
few TUNEL-positive cells were present in wild-type mice, and
staining was faint compared with transgenic mice (Fig. 5B). As
negative control, we omitted the POD convert solution (Fig.
5C), and, as a positive control, we pretreated sections with
DNase I (Fig. 5D). No TUNEL-positive neurons were identified
in the hippocampus of transgenic mice (data not shown). We
correlated numbers of HT7-positive neurons with glial fibril-
lary acidic protein-positive astrocytes and TUNEL reactivity in
the somatosensory cortex and counted per visual field 50 (614)
HT7-positive neurons, 19 (66) activated astrocytes, and 7 (63)
dark TUNEL-positive cells in transgenic brain compared with
no HT7-positive neurons, 5 (62) activated astrocytes, and 3
(63) faint TUNEL-positive cells in the wild-type control (Fig.
4C). To correlate astrocytosis and tau expression in different
brain areas, we compared in transgenic brain motor cortex M1
and somatosensory cortex S1 and counted per visual field 14
(64) HT7-positive neurons and 5 (61) activated astrocytes in
the M1 cortex compared with 50 (614) HT7-positive neurons
and 19 (66) activated astrocytes in the S1 cortex (Fig. 4D).
Tau Filaments—We prepared sarcosyl protein extracts for
electron microscopy analyses in parallel from brain tissue of an
AD patient, 8-month-old pR5 transgenic mice, and control mice
and found tau filaments in both AD and transgenic mouse
brains. The tau filaments in AD brain had a width of ;20 nm
(Fig. 6, A and B), and those in transgenic mice were ;15 nm
wide and significantly shorter (Fig. 6C). No such filaments
were present in any of the control mice (data not shown). To
identify phosphoepitopes of tau, we incubated the filaments
with a panel of phosphorylation-dependent antibodies. Immu-
nogold electron microscopy of extracts obtained from AD (Fig.
6, D and F) and pR5 transgenic (Fig. 6, E and G) brains using
TG3 (Fig. 6, D and E) or AT8 (Fig. 6, F and G) identified several
6-nm, gold-decorated filaments. These filaments were also
stained by the antibodies AT100 and AD199 (data not shown).
In AD brains, tau filaments consist of two structurally distinct
parts, the core and the fuzzy coat. The known, darkly stained
space between the filaments and the gold particles typically
corresponds to the known fuzzy coat of the filaments (10, 16).
No filaments were identified or decorated by gold-labeled an-
tibodies in negative controls, proving the specificity of these
antibodies. In particular, we found no neurofilaments, with a
width of 10 nm and an axial periodicity of 21 nm in the
preparation (17).
DISCUSSION
The results of this study show that transgenic expression of
human P301L mutant tau under control of the murine Thy1.2
genomic expression vector leads to the formation of sarcosyl-
insoluble, 15-nm-wide tau filaments. By comparison, tau fila-
ments in frontotemporal dementia with parkinsonism linked to
chromosome 17 patients with the P301L mutation (Dutch fam-
ily 1) consist of 15-nm-wide, slender, twisted filaments with
variable periodicity, in addition to a few straight filaments (1),
FIG. 3. Tau phosphorylation and conformational changes in
P301L tau transgenic mice. Antibody TG3, a phosphorylation- and
conformation-dependent antibody, stains pyramidal neurons of the CA1
region of the hippocampus of transgenic mice (A), but not controls (B).
Also in cortex, numerous pyramidal neurons are stained by this anti-
body in transgenic mice (C), but not controls (D). The conformation-de-
pendent antibody MC1 stains pyramidal neurons of the CA1 region and
the cortex of transgenic mice (E and G) but not controls (F and H). The
same staining pattern is obtained with phosphorylation-dependent an-
tibody AT180 (I–M). Scale bars: A–D, 30 mm; E–M, 30 mm.
FIG. 4. A, activated astrocytes are detected in those cortical areas of
transgenic mice that contain numerous tau-positive neurons. B, no such
activated astrocytes are found in control cortex. C and D, In the somato-
sensory cortex S1, 50 (614) HT7-positive neurons, 19 (66) activated
astrocytes, and 7 (63) dark TUNEL-positive cells are present per visual
field in transgenic brains, compared with no HT7-positive neurons, 5
(62) activated astrocytes, and 3 (63) faint TUNEL-positive cells in
wild-type controls (C). Astrocytosis and tau expression are positively
correlated in different brain areas of transgenic mice: per visual field,
14 (64) HT7-positive neurons and 5 (61) activated astrocytes are pres-
ent in the M1 cortex, compared with 50 (614) HT7-positive neurons and
19 (66) activated astrocytes in the S1 cortex (D).
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and the tau filaments obtained from AD brains consist of 20-
nm-wide, paired helical or straight filaments. The filaments in
our P301L tau transgenic mice have the same width as those in
the human disease associated with the P301L mutation (Dutch
family 1). They were, however, shorter than filaments enriched
from AD brains, which we included as positive control because
of the unavailability of a brain sample from Dutch family 1.
One likely explanation for the prevalence of short filaments in
our mice is that the longest tau isoform expressed in our mouse
contained two calpain recognition motifs for proteolytic degra-
dation that may favor the formation of shorter filaments. In
addition to the P301L mutation, the filament formation in our
mice may also be related to high expression levels achieved by
using the murine Thy1.2 expression vector, as shown by im-
munoblot analyses. A possible contribution of high expression
levels to tau filament formation in our mouse lines is supported
by the concentration dependence of filament assembly in vitro
that resembles a nucleation-dependent process (18, 19). To-
gether, the failure of previous attempts to model tau filament
formation in transgenic mice may be related to either the
absence of disease-causing mutations in the expression con-
structs or low expression levels (11, 20–25) or both.
In our mice, the murine Thy1.2 promoter directed expression
of tau mainly to hippocampal and cortical neurons. Brain re-
gions, which in human disease are spared from tau pathology,
such as the cerebellum, did not express detectable levels of tau,
as determined by immunofluorescence. As in human tauopa-
thies (26), tau accumulated not only in axons but also in cell
bodies and dendrites. To establish phosphoepitopes that are
related to tau aggregation and filament formation, we used a
panel of phosphorylation-dependent antibodies. In brains from
patients of Dutch family 1, phosphorylation-dependent anti-
bodies AT8, AT100, AT180, AT270, PHF1, and 12E8 stained
numerous deposits in several brain regions, including the cor-
tex, the dentate gyrus, and the CA1 region of the hippocampus.
These deposits were mainly of the pretangle type and located in
the perinuclear region and cell body and sometimes extended to
the apical dendrites of neurons (1). In our model, AT100 and
12E8 did not discriminate wild-type from transgenic mice. AT8
staining was weak in transgenic mice and mainly restricted to
a subset of cortical neurons, where it was found not only in cell
bodies but also in dendrites. AT100 and PHF1 did not stain any
neuron at up to 6 months of age. Age may account for this
apparent difference between human disease and the mouse
model, especially because filaments obtained from 8-month-old
transgenic mice were AT100- and AT8-positive. AT180 and also
the conformation-dependent antibodies MC1 and TG3, which
were not included in the human study, revealed strong soma-
todendritic staining in both cortical and hippocampal pyrami-
dal neurons of transgenic mice. Antibodies MC1 and TG3 rec-
ognize a distinct pathological conformation of the tau molecule
in AD. In normal autopsy-derived brain tissue, tau is not
stained by these antibodies. Our data indicate that transgenic
tau underwent a conformational change favoring filament for-
mation. Indeed, by immunogold electron microscopy of sarco-
syl-insoluble tau protein, the AT8, AD199, AT100, and TG3
epitopes were identified on tau filaments in our P301L trans-
genic mice. For comparison, in the human study only one
antibody, AT8, was used that labeled tau filaments (1). The
distance of the gold particles from the core of the filament is
similar to that reported for AD filaments (10). The space be-
tween the filaments and the gold particles corresponds to the
known fuzzy coat of the filaments (10, 16). Taken together, tau
in the nonfilamentous and filamentous states is hyperphospho-
rylated at several sites, which are also hyperphosphorylated in
human tauopathies.
In Dutch family 1, neurological examination of brains re-
vealed gliosis and severe neuronal loss in frontal and temporal
FIG. 6. Neuronal tau filaments in 8-month-old P301L tau trans-
genic brain revealed by electron microscopy and immunogold
electron microscopy of sarcosyl extracts. A and B, tau filaments in
an extract obtained from an AD brain have a width of ;20 nm. C, Tau
filaments in an extract obtained from the pR5 brain are shorter and
have a width of ;15 nm (arrows). No such filaments were identified in
sarcosyl extracts of control mice. D and E, immunogold electron micros-
copy of extracts obtained from AD (D) and pR5 brain (E) using phos-
phorylation- and conformation-dependent antibody TG3 identifies
6-nm, gold-decorated filaments. F and G, immunogold electron micros-
copy of extracts obtained from AD (F) and pR5 brain (G) using phos-
phorylation-dependent antibody AT8 also identifies 6-nm, gold-deco-
rated filaments. Scale bars: A, 400 nm; B and C, 80 nm; D–-G, 80 nm.
FIG. 5. TUNEL staining reveals neurons undergoing apoptosis
in transgenic mice. A and B, in cortical areas of transgenic mice that
contain numerous tau-positive neurons, many TUNEL-positive neu-
rons are identified (A), which are absent from controls (B). Arrows point
to some positive neurons. C and D, negative control without reagent (C)
and positive control, pretreated with DNase I (D).
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cortex and variable loss in the parietal cortex, whereas the
hippocampus showed only mild to moderate neuronal loss and
gliosis (1). These data are consistent with our findings. Despite
comparable levels and phosphorylation of human tau in hip-
pocampus and cortex of transgenic mice, we found evidence for
apoptosis and astrocytosis in cortical areas and in the amyg-
dala but not in the hippocampus. Astrocytosis was positively
correlated with levels of human tau expression, as shown for
the M1 and S1 cortices. Therefore, we cannot exclude the pos-
sibility that this pathology progresses and will include the
hippocampus with advanced aging in older mice.
Together, our data show that the P301L mutation in combi-
nation with high expression levels can cause the formation of
abnormal tau filaments in neurons in mice. Filament formation
was also reported recently in mice expressing 22324R tau,
along with the human pathogenic mutation P301L, under con-
trol of the mouse prion protein promoter. These mice show an
advanced neurological phenotype, likely reflecting differences
between 22324R and 21314R tau (27). In our P301L mice,
filaments were phosphorylated at distinct epitopes, and their
formation was accompanied by astrocytosis and apoptosis.
These data indicate that P301L is a key pathogenic factor, and
they underscore its pathophysiological role in frontotemporal
dementia with parkinsonism linked to chromosome 17. More-
over, our results suggest the use of these mice, either alone or
in combination with a pathogenic APP mutation, for the study
of both the pathophysiology and the prevention of tau filament
formation in neurodegenerative diseases.
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